Ovulation Induction Treatment,Ovulation Induction in Women,Ovulation Induction Center

We have a vast experience and perfection for Ovulation Induction in women. In our ovulation induction center, the maladies like hormonal balance is examined minutely in our labs and cured from the roots. In addition, we have a record that after our ovulation induction treatment, there has been no negative feedbacks as every client has been satisfied heartily. World is getting beneficiated from our Ovulation Induction Treatment at the rates that hardly matters.

The female reproductive cycle is regulated by hormones under the control of the hypothalamus, the pituitary gland and the ovaries. If this basic control system does not work correctly, ovulation will be disturbed or absent. Ovulatory disorders are characterized by anovulation (complete failure to ovulate) or infrequent and/or irregular ovulation.
The WHO has adopted a treatment-oriented classification of anovulating patients :-

Group I patients have hypothalmic-pituitary failure. They are amenorrheic and lack both follicle stimulating hormone (FSH) and luteinizing hormone (LH).

Group II patients have hypothalmic-pituitary dysfunction and present with a variety of cycle disorders including amenorrhoea, oligomenorrhoea and luteal phase deficiencies. About 97% of anovulatory patient fall into this group, including polycystic ovarian disease (PCOD, a condition commonly characterized by hirsutism, obesity, menstrual abnormalities, infertility and enlarged ovaries; thought to reflect excessive androgen secretion of ovarian origin), which is thought to be the most common cause of ovarian dysfunction.
Ovulation induction (OI) aims to correct hormonal imbalances, allowing where possible, monoovulation to occur. More than 80% of infertile women anatomical disorders are treated successfully with fertility agents that promote the growth and development of ovarian follicles vis stimulation of FSH and LH.
Agents most commonly used for ovulationinduction are:

Clomiphene citrate, acting on the hypothalamus to increase the release of gonadotropin releasing hormone (GnRH), which, in turn, stimulate the pituitary gland to release FSH and LH.

Gonadotropins (FSH and LH acting directly on the ovary, promoting follicular development and hCG triggering ovulation after follicular stimulation).
In WHO Group I patients, Gonadotropin therapy with both FSH and LH is required for follicular development and ovulation. WHO Group II patients may respond to clomiphene citrate. FSH treatment is normally reserved for those who do not respond to clomiphene.
OI is usually combined with timed intercourse or with artificial insemination (also called intrauterine insemination - IUI) in order to increase the probability of successful fertilization. If conception has not taken place after approximately three to five cycles with clomiphene citrate and a further three to five cycles with Gonadotropin treatment, the patient may be referred for ART. The number for clomiphene citrate/Gonadotropin treatment courses is related to the type of infertility, the result of the investigations and reimbursement schemes practiced in each individual country.
FSH is effective in ovarian stimulation. Human chorionic gonadotropin (hCG) injections are used in conjunction with FSH to provoke egg release (hCG is given to mimic the natural LH surge). A frequent adjunct to FSH therapy is synthetic luteinizing hormone releasing hormone (LHRH) analogues which work by suppressing the ovaries. In their suppressed state, the ovaries are more receptive to FSH therapy and higher quality eggs are produced as a result. This is particularly useful for women with PCOD not responding to FSH alone.
Bromocriptine is a useful agent in the treatment of hyperprolactinemia, a condition where there is excess of the hormone prolactin in the blood. This condition results in the suppression of GnRH release contributing to anovulation.